Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Bio-Thera Solutions Announces First Patient Dosed in Study for the Treatment of Advanced Solid Tumors
Bio-Thera Solutions, a commercial-stage pharmaceutical company, has announced that dosing has begun in a Phase […]
CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland
CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
QIAGEN today announced it has entered into a strategic partnership with Servier, a global pharmaceutical […]
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
Telix Pharmaceuticals today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and […]
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma
JW Therapeutics, an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell […]
Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy
Virion Therapeutics, a clinical-stage biotech company focused on the development of novel, adaptable, and accessible CD8+ T […]
Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases
Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other […]
Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer
Point32Health, the parent company of Harvard Pilgrim Health Care and Tufts Health Plan, and Foundation […]
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics and Dynacure announced today that the companies have signed a definitive merger agreement to […]
Debiopharm Extends Their DNA Damage Repair Footprint With New Oncology Pipeline Entry
Debiopharm, an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more